| Literature DB >> 30832446 |
Alexandros Patsilinakos1,2, Marco Artini3, Rosanna Papa4, Manuela Sabatino5, Mijat Božović6, Stefania Garzoli7, Gianluca Vrenna8, Raissa Buzzi9, Stefano Manfredini10, Laura Selan11, Rino Ragno12,13.
Abstract
Biofilm resistance to antimicrobials is a complex phenomenon, driven not only by genetic mutation induced resistance, but also by means of increased microbial cell density that supports horizontal gene transfer across cells. The prevention of biofilm formation and the treatment of existing biofilms is currently a difficult challenge; therefore, the discovery of new multi-targeted or combinatorial therapies is growing. The development of anti-biofilm agents is considered of major interest and represents a key strategy as non-biocidal molecules are highly valuable to avoid the rapid appearance of escape mutants. Among bacteria, staphylococci are predominant causes of biofilm-associated infections. Staphylococci, especially Staphylococcus aureus (S. aureus) is an extraordinarily versatile pathogen that can survive in hostile environmental conditions, colonize mucous membranes and skin, and can cause severe, non-purulent, toxin-mediated diseases or invasive pyogenic infections in humans. Staphylococcus epidermidis (S. epidermidis) has also emerged as an important opportunistic pathogen in infections associated with medical devices (such as urinary and intravascular catheters, orthopaedic implants, etc.), causing approximately from 30% to 43% of joint prosthesis infections. The scientific community is continuously looking for new agents endowed of anti-biofilm capabilities to fight S. aureus and S epidermidis infections. Interestingly, several reports indicated in vitro efficacy of non-biocidal essential oils (EOs) as promising treatment to reduce bacterial biofilm production and prevent the inducing of drug resistance. In this report were analyzed 89 EOs with the objective of investigating their ability to modulate bacterial biofilm production of different S. aureus and S. epidermidis strains. Results showed the assayed EOs to modulated the biofilm production with unpredictable results for each strain. In particular, many EOs acted mainly as biofilm inhibitors in the case of S. epidermidis strains, while for S. aureus strains, EOs induced either no effect or stimulate biofilm production. In order to elucidate the obtained experimental results, machine learning (ML) algorithms were applied to the EOs' chemical compositions and the determined associated anti-biofilm potencies. Statistically robust ML models were developed, and their analysis in term of feature importance and partial dependence plots led to indicating those chemical components mainly responsible for biofilm production, inhibition or stimulation for each studied strain, respectively.Entities:
Keywords: Staphylococcus species; antimicrobial; biofilm; essential oil; machine learning
Mesh:
Substances:
Year: 2019 PMID: 30832446 PMCID: PMC6429525 DOI: 10.3390/molecules24050890
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
MIC determined for CGEOs on S. spp strains. EOID indicates samples names. Sample names are the same as previously reported [22]. Ofloxacin MIC is also reported as a positive reference drug. All data are expressed in mg/mL.
| EOID | ||||
|---|---|---|---|---|
| CJ1 | >25 | >25 | >25 | >25 |
| CJ2 | >25 | >25 | 50 | >25 |
| CJ3 | 25 | 25 | >25 | >25 |
| CJ6 | 25 | 25 | >25 | >25 |
| CJ12 | 25 | >25 | >25 | >25 |
| CJ24 | >25 | >25 | >25 | >25 |
| CJM1 | 12.5 | 25 | >25 | >25 |
| CJM2 | >25 | >25 | >25 | >25 |
| CJM3 | 12.5 | 25 | 25–12.5 | 25–12.5 |
| CJM4 | 12.5 | 25 | 25 | >25 |
| CJM5 | >25 | >25 | >25 | >25 |
| CA1 | >25 | >25 | >25 | >25 |
| CA2 | >25 | >25 | >25 | >25 |
| CA3 | 25 | >25 | >25 | >25 |
| CA6 | 25–12.5 | >25 | 25 | 25 |
| CA12 | 12.5 | 12.5 | 12.5 | >25 |
| CA24 | 12.5 | 12.5 | >25 | >25 |
| CAM1 | >25 | >25 | >25 | >25 |
| CAM2 | 12.5–6.25 | 12.5–6.25 | 12.5 | 12.5 |
| CAM3 | >25 | >25 | >25 | >25 |
| CAM4 | 6.25 | 6.25 | 12.5 | 12.5 |
| CAM5 | >25 | >25 | >25 | >25 |
| CS1 | >25 | >25 | >25 | >25 |
| CS2 | >25 | >25 | >25 | >25 |
| CS3 | >25 | >25 | >25 | >25 |
| CS6 | >25 | >25 | >25 | >25 |
| CS12 | 12.5–6.25 | 12.5 | 12.5 | 12.5 |
| CS24 | 6.25 | 12.5–6.25 | >25 | 12.5 |
| CSM1 | >25 | >25 | >25 | >25 |
| CSM2 | 12.5 | 12.5 | 12.5 | 12.5 |
| CSM3 | >25 | >25 | >25 | >25 |
| CSM4 | 12.5–6.25 | 12.5–6.25 | 12.5 | 12.5 |
| CSM5 | >25 | >25 | >25 | >25 |
| CO1 | >25 | >25 | >25 | >25 |
| CO2 | >25 | >25 | >25 | >25 |
| CO3 | 25–12.5 | 25 | 25 | 25 |
| CO6 | 25–12.5 | 25–12.5 | 25–12.5 | 25–12.5 |
| CO12 | 12.5 | 12.5 | 12.5 | 12.5 |
| CO24 | >25 | >25 | >25 | >25 |
| COM1 | 25 | 25 | 25–12.5 | 25–12.5 |
| COM2 | 25–12.5 | 25–12.5 | 25–12.5 | 25–12.5 |
| COM3 | 25 | 25 | 25–12.5 | 25–12.5 |
| COM4 | 12.5 | 25 | 25 | 25 |
| COM5 | >25 | >25 | >25 | >25 |
| Ofloxacin | 0.0002–0.0004 | 0.0004–0.0008 | 0.0002–0.0004 | 0.0002–0.0004 |
MIC determined for FVEOs samples on S. spp strains. EOID indicates samples names. Sample names are the same as previously reported [22]. Ofloxacin MIC is also reported as a positive reference drug. All data are expressed in mg/mL.
| EOID | ||||
|---|---|---|---|---|
| FA1 | >25 | >25 | >25 | >25 |
| FA2 | 25–12.5 | 25–12.5 | >25 | >25 |
| FA3 | >25 | >25 | >25 | >25 |
| FA6 | >25 | >25 | >25 | >25 |
| FA12 | >25 | >25 | >25 | >25 |
| FA24 | 12.5–6.25 | >25 | >25 | >25 |
| FAM1 | >25 | >25 | >25 | >25 |
| FAM2 | >25 | >25 | >25 | >25 |
| FAM3 | >25 | >25 | >25 | >25 |
| FAM4 | >25 | >25 | >25 | >25 |
| FAM5 | >25 | >25 | >25 | 25 |
| FS1 | >25 | >25 | >25 | >25 |
| FS2 | >25 | >25 | >25 | >25 |
| FS3 | >25 | >25 | >25 | >25 |
| FS6 | >25 | >25 | >25 | >25 |
| FS12 | >25 | >25 | >25 | >25 |
| FS24 | >25 | >25 | >25 | >25 |
| FSM1 | >25 | >25 | >25 | >25 |
| FSM2 | >25 | >25 | >25 | >25 |
| FSM3 | 12.5–6.25 | >25 | >25 | >25 |
| FSM4 | >25 | >25 | >25 | >25 |
| FSM5 | 25–12.5 | 12.5 | >25 | >25 |
| FO1 | 25 | 25 | >25 | >25 |
| FO2 | >25 | >25 | >25 | >25 |
| FO3 | 25 | 25 | >25 | >25 |
| FO6 | 25 | 25 | >25 | >25 |
| FO12 | >25 | >25 | >25 | >25 |
| FO24 | >25 | >25 | >25 | >25 |
| FOM1 | >25 | >25 | >25 | >25 |
| FOM2 | >25 | >25 | >25 | >25 |
| FOM3 | 25–12.5 | 12.5 | >25 | >25 |
| FOM4 | >25 | >25 | >25 | >25 |
| FOM5 | >25 | >25 | >25 | >25 |
| Ofloxacin | 0.0002–0.0004 | 0.0004–0.0008 | 0.0002–0.0004 | 0.0002–0.0004 |
MIC determined for RSEOs samples on S. spp strains. EOID indicates samples names. Sample names are the same as previously reported [22]. Ofloxacin MIC is also reported as a positive reference drug. All data are expressed in mg/mL.
| EOID | ||||
|---|---|---|---|---|
| R1 | >25 | >25 | >25 | >25 |
| R2 | >25 | >25 | >25 | >25 |
| R3 | >25 | >25 | >25 | >25 |
| R6 | >25 | >25 | >25 | >25 |
| R12 | >25 | >25 | >25 | >25 |
| R24 | 25 | >25 | >25 | >25 |
| R30 | 25 | 25 | 25 | 25 |
| RM1 | >25 | >25 | >25 | >25 |
| RM2 | >25 | >25 | >25 | >25 |
| RM3 | >25 | >25 | >25 | >25 |
| RM4 | >25 | >25 | >25 | >25 |
| RM5 | >25 | >25 | >25 | >25 |
| RM6 | >25 | >25 | >25 | >25 |
| Ofloxacin | 0.0002–0.0004 | 0.0004–0.0008 | 0.0002–0.0004 | 0.0002–0.0004 |
Figure 1Percentages of biofilm production after treatment at two concentrations (3.125 mg/mL and 0.0488 mg/mL) for RSEOs against the four strains S. aureus 6538P (A) and 25923 (B), S. epidermidis RP62A (C) and O-47 (D, respectively). In the ordinate axis are reported the percentage of bacterial biofilm production. Data are reported as percentage of residual biofilm after the treatment in comparison with the untreated one. Each data point is composed of 4 independent experiments each performed with at least three replicates.
Figure 2Percentages of biofilm production after treatment at two concentrations (3.125 mg/mL and 0.0488 mg/mL) for FVEOs against the four strains S. aureus 6538P (A) and 25923 (B), S. epidermidis RP62A (C) and O-47 (D, respectively). In the ordinate axis are is reported the percentage of bacterial biofilm production. Data are reported as percentage of residual biofilm after the treatment in comparison with the untreated one. Each data point is composed of 4 independent experiments each performed with at least three replicates.
Figure 3Percentages of biofilm production after treatment at two concentrations (3.125 mg/mL and 0.0488 mg/mL) for CGEOs against the four strains S. aureus 6538P (A) and 25923 (B), S. epidermidis RP62A (C) and O-47 (D), respectively). In the ordinate axis are is reported the percentage of bacterial biofilm production. The abscissa axis is centered at 100% biofilm production. Data are reported as percentage of residual biofilm after the treatment in comparison with the untreated one. Each data point is composed of 4 independent experiments each performed with at least three replicates.
Data analysis of biofilm production modulation by EOs at the two selected concentrations as reported in Figure 1, Figure 2 and Figure 3. In pale green background are depicted biofilm inhibition values, while in pale red background are highlighted biofilm enhanced data.
| Conc. μg/mL | Biofilm Production % | Number EOs Samples at Biofilm Production % | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| MIN | MAX | <50% | <80% | <100% | ≥100% | ≥120% | ≥150% | ≥200% | ||
| 3125 | 6538P | 50.98 | 523.83 | 0 | 10 | 31 | 58 | 38 | 22 | 9 |
| 25923 | 26.92 | 697.45 | 1 | 4 | 16 | 73 | 47 | 14 | 9 | |
| RP62A | 13.04 | 209.69 | 26 | 42 | 71 | 18 | 8 | 1 | 1 | |
| O-47 | 27.12 | 289.88 | 24 | 35 | 61 | 28 | 14 | 4 | 4 | |
| 48.8 | 6538P | 62.80 | 459.46 | 0 | 5 | 20 | 69 | 37 | 17 | 7 |
| 25923 | 37.91 | 501.01 | 3 | 34 | 67 | 22 | 10 | 7 | 3 | |
| RP62A | 11.79 | 202.57 | 29 | 48 | 74 | 15 | 6 | 2 | 1 | |
| O-47 | 0.44 | 306.60 | 31 | 48 | 74 | 15 | 7 | 4 | 2 | |
Figure 4Antibiofilm effect of selected RSEOs on RP62A and on O-47 strains. In the ordinate axis is reported the percentage of bacterial biofilm production. Data are reported as percentage of residual biofilm after the treatment in comparison with the untreated one. Each data point is composed of 4 independent experiments each performed with at least in three replicates.
Figure 5Antibiofilm effect of selected FVEOs on RP62A and on O-47 strains. In the ordinate axis is reported the percentage of bacterial biofilm production. Data are reported as percentage of residual biofilm after the treatment in comparison with the untreated one. Each data point is composed of 4 independent experiments each performed with at least three replicates.
Figure 6Antibiofilm effect of selected CGEOs on RP62A and on O-47 strains. In the ordinate axis is reported the percentage of bacterial biofilm production. Data are reported as percentage of residual biofilm after the treatment in comparison with the untreated one. Each data point is composed of 4 independent experiments each performed with at least three replicates.
Characteristics of the grid search optimized models.
| Assayed Conc. (μg/mL) | Models’ Parameters | Biofilm Inhibition Models | Biofilm Activation Models | |||||
|---|---|---|---|---|---|---|---|---|
| RP62A | O-47 | 25923 | RP62A | O-47 | 6538P | 25923 | ||
| 3125 | PCs 1 | 5 | 19 | 22 | 9 | 12 | 9 | 25 |
| Actives 2 | 31 | 30 | 4 | 6 | 4 | 27 | 20 | |
| Non-actives 3 | 58 | 59 | 85 | 83 | 85 | 62 | 69 | |
| cutoff | 62 | 62 | 63 | 126 | 133 | 139 | 139 | |
| 48.8 | PCs 1 | 8 | 9 | 24 | 15 | 8 | 9 | 20 |
| Actives 2 | 32 | 30 | 3 | 7 | 4 | 30 | 45 | |
| Non-actives 3 | 57 | 59 | 86 | 82 | 85 | 59 | 44 | |
| Cutoff4 | 63 | 63 | 62 | 124 | 138 | 133 | 121 | |
1: number of principal components used in the model; 2: number of EOs as inhibitors or enhancers of bacterial biofilm production: 3: number of EOs as non-inhibitors or not-enhancers of biofilm production; 4: optimal values of bacterial biofilm production percentage for binary classification as inhibitors/non-inhibitors or enhancers/not-enhancers of bacterial biofilm production.
Fitted and cross-validated Accuracy, MCC, Precision-Recall and ROC-AUC coefficients for the RP62A/inhibition, O-47/inhibition, 6538P/activation and 259237/activation optimized models at 3.125 mg/mL and 0.0488 μg/mL.
| Validation | Assayed Conc. (μg/mL) | Coefficient | Biofilm Inhibition Models | Biofilm Activation Models | ||
|---|---|---|---|---|---|---|
| RP62A | O-47 | 6538P | 25923 | |||
| Fitting | 3125 | Accuracy | 0.721 | 0.771 | 0.832 | 0.906 |
| MCC | 0.455 | 0.590 | 0.667 | 0.826 | ||
| Precision-Recall | 0.657 | 0.682 | 0.772 | 0.956 | ||
| ROC-AUC | 0.742 | 0.753 | 0.824 | 0.961 | ||
| 48.8 | Accuracy | 0.722 | 0.780 | 0.806 | 0.763 | |
| MCC | 0.452 | 0.604 | 0.632 | 0.533 | ||
| Precision-Recall | 0.659 | 0.681 | 0.757 | 0.824 | ||
| ROC-AUC | 0.735 | 0.752 | 0.815 | 0.834 | ||
| Cross-Validation | 3125 | AccuracyCV | 0.687 | 0.738 | 0.805 | 0.784 |
| MCCCV | 0.392 | 0.517 | 0.613 | 0.568 | ||
| Precision-RecallCV | 0.584 | 0.589 | 0.698 | 0.782 | ||
| ROC-AUCCV | 0.683 | 0.659 | 0.743 | 0.845 | ||
| 48.8 | AccuracyCV | 0.663 | 0.721 | 0.722 | 0.606 | |
| MCCCV | 0.335 | 0.474 | 0.450 | 0.214 | ||
| Precision-RecallCV | 0.577 | 0.591 | 0.668 | 0.533 | ||
| ROC-AUCCV | 0.666 | 0.660 | 0.753 | 0.599 | ||
Chance correlation control by Y-scrambling procedure results. Mean, standard deviation (St Dev), maximum (max) and minimum (min) values for AccuracyY-S, MCCY-S, Precision-RecallY-S and ROC-AUCY-S ROC-AUC coefficients for cross-validated 100 runs. Values refer to RP62A/inhibition, O-47/inhibition, 6538P/activation and 259237/activation optimized models at 3.125 mg/mL.
| Type of Model | Strain | Coefficient | Mean | St Dev | Max | Min |
|---|---|---|---|---|---|---|
| Biofilm Inhibition Models | RP62A | AccuracyY-S | 0.500 | 0.079 | 0.644 | 0.219 |
| MCCY-S | 0.000 | 0.159 | 0.290 | −0.567 | ||
| Precision-RecallY-S | 0.496 | 0.063 | 0.643 | 0.353 | ||
| ROC-AUCY-S | 0.459 | 0.094 | 0.627 | 0.198 | ||
| O-47 | AccuracyY-S | 0.494 | 0.081 | 0.665 | 0.286 | |
| MCCY-S | −0.011 | 0.164 | 0.342 | −0.429 | ||
| Precision-RecallY-S | 0.506 | 0.068 | 0.668 | 0.377 | ||
| ROC-AUCY-S | 0.474 | 0.089 | 0.645 | 0.241 | ||
| Biofilm Activation Models | 6538P | AccuracyY-S | 0.492 | 0.082 | 0.637 | 0.249 |
| MCCY-S | −0.017 | 0.169 | 0.275 | −0.522 | ||
| Precision-RecallY-S | 0.507 | 0.071 | 0.661 | 0.347 | ||
| ROC-AUCY-S | 0.470 | 0.100 | 0.644 | 0.166 | ||
| 25923 | AccuracyY-S | 0.508 | 0.083 | 0.680 | 0.292 | |
| MCCY-S | 0.013 | 0.170 | 0.361 | −0.433 | ||
| Precision-RecallY-S | 0.524 | 0.071 | 0.746 | 0.355 | ||
| ROC-AUCY-S | 0.490 | 0.102 | 0.675 | 0.179 |
Figure 7Feature importance plot for the 6538P/activation model defined at 3.125 mg/mL.
Feature importances for each chemical component as derived by the SKATER algorithm for the RP62A/inhibition, O-47/inhibition, 6538P/activation and 259237/activation optimized models at 3.125 mg/mL. Background of more important chemical component for inhibition are colored in darker green, while in darker red background are highlighted components associated to higher biofilm production enhancement.
| Chemical Component | Biofilm Inhibition Models | Biofilm Inhibition Models | ||
|---|---|---|---|---|
| RP62A | O-47 | 6538P | 25923 | |
| 2-Hydroxypiperitenone | 0.23 | 0.32 | 0.38 | 0.44 |
| 2,3-Pinanediol | 1.33 | 4.07 | 1.47 | 1.05 |
| 3-Methylcyclohexanone | 0.16 | 0.45 | 1.09 | 1.62 |
| 3-Octanol | 6.47 | 7.16 | 10.80 | 4.44 |
| 4-Terpineol | 1.99 | 1.81 | 3.65 | 3.57 |
| α-Phellandrene | 0.61 | 0.30 | 3.02 | 0.67 |
| α-Pinene | 2.71 | 2.98 | 1.00 | 0.21 |
| α-Terpineol | 2.40 | 3.32 | 2.81 | 2.22 |
| Apiol | 0.17 | 0.78 | 0.83 | 0.97 |
| β-Cymene | 1.46 | 1.35 | 2.42 | 6.37 |
| β-Linalool | 1.40 | 1.08 | 0.93 | 7.08 |
| β-Myrcene | 0.72 | 0.05 | 0.95 | 0.67 |
| β-Ocimene | 0.56 | 1.75 | 0.78 | 0.06 |
| β-Phellandrene | 1.62 | 5.42 | 3.30 | 0.69 |
| β-Pinene | 1.31 | 1.15 | 0.34 | 2.12 |
| β-Terpinene | 0.17 | 0.63 | 0.97 | 0.15 |
| Borneol | 0.07 | 0.25 | 0.45 | 0.56 |
| Carvacrol | 0.38 | 0.38 | 0.34 | 0.26 |
| Caryophyllene | 1.35 | 1.67 | 2.78 | 4.36 |
| Caryophyllene oxide | 0.13 | 1.23 | 0.32 | 3.25 |
| Chrysanthenone | 3.87 | 3.58 | 2.68 | 4.79 |
| Cinerolone | 1.14 | 0.40 | 0.64 | 1.45 |
| 0.55 | 0.55 | 0.88 | 1.85 | |
| 4.60 | 3.40 | 4.36 | 0.17 | |
| Citral | 0.12 | 0.39 | 0.65 | 0.99 |
| Cryptone | 0.15 | 1.63 | 0.09 | 0.27 |
| 5.66 | 6.29 | 9.22 | 1.56 | |
| delta-Cadinene | 1.62 | 0.90 | 0.40 | 1.17 |
| Estragole | 3.87 | 3.21 | 0.04 | 2.49 |
| Fenchone | 3.66 | 3.08 | 0.06 | 1.54 |
| γ-Terpinene | 0.19 | 1.14 | 1.51 | 1.97 |
| Germacrene D | 0.82 | 0.65 | 0.65 | 0.14 |
| Isocaryophyllene | 0.86 | 0.58 | 0.84 | 0.07 |
| Isomenthone | 1.53 | 0.26 | 0.71 | 1.77 |
| Isopiperitenone | 2.80 | 2.38 | 1.61 | 2.42 |
| Isopulegone | 0.01 | 0.63 | 4.89 | 0.85 |
| Limonene | 1.64 | 4.02 | 2.62 | 0.67 |
| Menthol | 2.17 | 1.30 | 1.38 | 7.16 |
| Menthone | 3.00 | 3.07 | 3.81 | 7.51 |
| Methyl isopulegone | 0.27 | 0.14 | 0.27 | 0.13 |
| Myristicin | 4.16 | 2.48 | 0.16 | 0.59 |
| 2.64 | 6.40 | 3.44 | 1.62 | |
| 0.90 | 1.76 | 0.89 | 0.96 | |
| 2.99 | 0.02 | 0.39 | 1.14 | |
| 5.06 | 0.89 | 1.51 | 0.91 | |
| 0.43 | 0.33 | 0.26 | 0.35 | |
| Phellandral | 6.15 | 3.97 | 1.40 | 2.08 |
| Piperitenone | 0.21 | 0.03 | 2.86 | 4.95 |
| Piperitenone oxide | 2.32 | 0.46 | 1.68 | 0.36 |
| Pulegone | 4.06 | 4.10 | 9.12 | 4.18 |
| Sabinene | 0.61 | 0.62 | 0.91 | 0.62 |
| Terpinolene | 0.55 | 1.90 | 1.07 | 1.84 |
| Thymol | 5.73 | 2.94 | 0.08 | 0.31 |
| trans- | 0.43 | 0.33 | 0.26 | 0.35 |
Figure 8Feature importance plot for the 25923/activation model defined at 3.125 mg/mL.
Figure 9Feature importance plot for the RP62A/inhibition model defined at 3.125 mg/mL.
Figure 10Feature importance plot for the O-47/inhibition model defined at 3.125 mg/mL.
Details of the used bacterial strains.
| Strain | Name | Type | Isolation |
|---|---|---|---|
| 6538P | clinical isolate | ATCC collection | |
| 25923 | clinical isolate | ATCC collection | |
| RP62A | infected catheter isolated strain | ATCC collection | |
| O-47 | septic arthritis clinical isolate | Heilmann et al., 1996 [ |